Denmark’s pharmaceutical powerhouse Novo Nordisk has announced a landmark partnership with AI pioneer OpenAI, aiming to deliver “new and better treatment options to patients faster.”
The deal, revealed on Tuesday, will harness advanced artificial intelligence to sift through massive biological datasets, uncover promising therapies, and dramatically cut the time from research labs to patient care.
The collaboration comes at a pivotal moment for Novo, which is racing to innovate amid soaring demand for obesity and diabetes treatments. CEO Mike Doustdar emphasised the stakes.
“There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives. Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever.”
OpenAI chief Sam Altman praised the potential. “AI is reshaping industries and in life sciences, it can help people live better, longer lives.”
Investors welcomed the news, sending Novo Nordisk shares up 2.8% shortly after markets opened, in line with rising optimism about AI in biotech.
This move builds on a wave of AI enthusiasm across the sector, where companies like Pfizer and AstraZeneca are forging similar alliances to streamline drug development. While AI promises to revolutionise discovery, experts note its biggest immediate impact may lie in speeding up clinical trials by matching patients to studies more efficiently, a process that currently delays most projects.
Novo’s pact also extends its existing tie-up with Nvidia, using the Gefion supercomputer to fast-track early research. Locked in a fierce battle with U.S. rival Eli Lilly for dominance in the $100 billion weight-loss market by 2030, Novo is deploying its Wegovy tablet, launched in January, and next-gen drugs like CagriSema to reclaim ground lost to Lilly’s Zepbound.